Studyto compare the efficacy and safety of fingolimod and interferon-beta-1b in patients with mutliple sclerosis

• Conditions: treating of cognitive symptoms in relapsing-remitting multiple sclerosis; MedDRA version: 14.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disorders; Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

• Registration Number: EUCTR2010-023023-19-DE
• Lead Sponsor: ovartis Farma S.p.A.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-11-18
• Last Update Posted: 14 December 2015

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Written informed consent must be obtained before any assessment is performed. 2. Male or female subjects aged 18-60 years. 3. Patients with relapsing-remitting forms of MS (RRMS) defined by 2005 revised McDonald criteria (McDonald et al 2001; Polman et al 2005). 4. Patients with active disease, defined as at least one clinical relapse in the last year, or two clinical relapses in the last two years if there are signs of disease activity at one brain MRI scan performed in the last six months. 5. Patients with cognitive impairment at screening, defined as at least one test of the Rao’s Brief Repeatable Battery (BRB) with scores falling below the 10th percentile of the normative data (age- and gender-based).
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 160
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Patients who had already been treated with multiweekly interferon and had an unsatisfactory response according to the judgment of the investigator. Patients with hyperactive forms of the MS disease according to the judgment of the investigator. Patients with an EDSS>5. Patients with an acute relapse of MS. Patients with a prior or current diagnosis of Major Depression according to DSM-IV. Patients with a history of chronic disease of the immune system other than MS, atopic dermatitis, psoriasis or Hashimoto's Disease. History of malignancy of any organ system, within the past 5 years. Patients with uncontrolled diabetes mellitus (HbA1c >7%). Diagnosis of macular edema during Screening Phase. Patients with active systemic bacterial, viral or fungal infections, or known to have AIDS, Hepatitis B, Hepatitis C infection or to have positive HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody tests. Patients with negative test for varicella-zoster virus IgG antibodies at screening. If these patients elect to be vaccinated, they may return to be rescreened at least two month after the vaccination. Have received any live or live attenuated vaccines within 2 months prior to baseline. Patients who have received total lymphoid irradiation or bone marrow transplantation. Patients who have been treated with:?corticosteroids (systemic) or ACTH within 1 month prior to screening; immunosuppressive medications such as azathioprine or methotrexate within 3 months prior to baseline;?immunoglobulins and/or monoclonal antibodies within 3 months prior to baseline;?cladribine, cyclophosphamide any time, mitoxantrone in the last 12 month. Patients with any medically unstable condition, as assessed by the primary treating physician at each site. Patients with any of the following cardiovascular conditions or conditions for which significant bradycardia may be poorly tolerated: history of cardiac arrest; ? history of myocardial infarction or with known ischemic heart disease (including angina pectoris);? history of symptomatic bradycardia or recurrent syncope;
? cerebrovascular disease;? congestive heart failure;? severe untreated sleep apnea;?known history of angina pectoris due to coronary spasm or history of Raynaud’s phenomenon; cardiac failure at time of Screening (Class III) or any severe cardiac disease as determined by the investigator; history or presence of a Mobitz 2 second degree AV block or a third degree AV block or an increased QTc interval >450 ms in males and >470 ms in females corrected using Bazett’s formula; patients receiving Class Ia and III antitiarrhythmic drugs; patients receiving heart rate lowering drugs, e.g. beta-blockers, calcium channel blockers (e.g. verapamil, diltiazem or ivabradine) or other substances which may decrease heart rate (e.g. digoxin, anticholinesteratic agents or pilocarpine); resting pulse rate <45 bpm prior to baseline;?proven history of sick sinus syndrome or sino-atrial heart block; hypertension, not controlled by prescribed medications. Patients with any of the following pulmonary conditions:?pulmonary fibrosis;?active tuberculosis. Patients with any of the following hepatic conditions:?chronic liver or biliary disease;?total bilirubin greater than 2 times the upper limit of the normal range, unless in context of Gilbert’s syndrome; conjugated bilirubin greater than 2 times the upper limit of the normal range;?AST, ALT >2 times the upper limit of the normal range; AP >1.5 times the upper limit

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified